Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

Sherrif F. Ibrahim; Julia M. Kasprzak; Mary A. Hall; Alison L. Fitzgerald; Jennifer J. Siegel; Sarah J. Kurley; Kyle R. Covington; Matthew S. Goldberg; Aaron S. Farberg; Shannon C. Trotter; Kenneth Reed; David G. Brodland; Shlomo A. Koyfman; Ally Khan Somani; Sarah T. Arron; Ashley Wysong

doi:10.2217/fon-2021-1277

Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

Sherrif F. Ibrahim, Julia M. Kasprzak, Mary A. Hall, Alison L. Fitzgerald, Jennifer J. Siegel, Sarah J. Kurley, Kyle R. Covington, Matthew S. Goldberg, Aaron S. Farberg, Shannon C. Trotter, Kenneth Reed, David G. Brodland, Shlomo A. Koyfman, Ally Khan Somani, Sarah T. Arron, Ashley Wysong

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.

Original language	English (US)
Pages (from-to)	833-847
Number of pages	15
Journal	Future Oncology
Volume	18
Issue number	7
DOIs	https://doi.org/10.2217/fon-2021-1277
State	Published - Mar 2022

Keywords

clinicopathologic risk factors
cutaneous squamous cell carcinoma
gene expression profile
informed decision-making
metastasis/metastatic risk

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2021-1277

Cite this

Ibrahim, S. F., Kasprzak, J. M., Hall, M. A., Fitzgerald, A. L., Siegel, J. J., Kurley, S. J., Covington, K. R., Goldberg, M. S., Farberg, A. S., Trotter, S. C., Reed, K., Brodland, D. G., Koyfman, S. A., Somani, A. K., Arron, S. T., & Wysong, A. (2022). Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test. Future Oncology, 18(7), 833-847. https://doi.org/10.2217/fon-2021-1277

Ibrahim, SF, Kasprzak, JM, Hall, MA, Fitzgerald, AL, Siegel, JJ, Kurley, SJ, Covington, KR, Goldberg, MS, Farberg, AS, Trotter, SC, Reed, K, Brodland, DG, Koyfman, SA, Somani, AK, Arron, ST & Wysong, A 2022, 'Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test', Future Oncology, vol. 18, no. 7, pp. 833-847. https://doi.org/10.2217/fon-2021-1277

@article{4573450e18bd4ded96c61be7d2a0f427,

title = "Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test",

abstract = "Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.",

keywords = "clinicopathologic risk factors, cutaneous squamous cell carcinoma, gene expression profile, informed decision-making, metastasis/metastatic risk",

author = "Ibrahim, {Sherrif F.} and Kasprzak, {Julia M.} and Hall, {Mary A.} and Fitzgerald, {Alison L.} and Siegel, {Jennifer J.} and Kurley, {Sarah J.} and Covington, {Kyle R.} and Goldberg, {Matthew S.} and Farberg, {Aaron S.} and Trotter, {Shannon C.} and Kenneth Reed and Brodland, {David G.} and Koyfman, {Shlomo A.} and Somani, {Ally Khan} and Arron, {Sarah T.} and Ashley Wysong",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors.",

year = "2022",

month = mar,

doi = "10.2217/fon-2021-1277",

language = "English (US)",

volume = "18",

pages = "833--847",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "7",

}

TY - JOUR

T1 - Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

AU - Ibrahim, Sherrif F.

AU - Kasprzak, Julia M.

AU - Hall, Mary A.

AU - Fitzgerald, Alison L.

AU - Siegel, Jennifer J.

AU - Kurley, Sarah J.

AU - Covington, Kyle R.

AU - Goldberg, Matthew S.

AU - Farberg, Aaron S.

AU - Trotter, Shannon C.

AU - Reed, Kenneth

AU - Brodland, David G.

AU - Koyfman, Shlomo A.

AU - Somani, Ally Khan

AU - Arron, Sarah T.

AU - Wysong, Ashley

PY - 2022/3

Y1 - 2022/3

N2 - Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.

AB - Aim: To clinically validate the 40-gene expression profile (40-GEP) test for cutaneous squamous cell carcinoma patients and evaluate coupling the test with individual clinicopathologic risk factor-based assessment methods. Patients & methods: In a 33-site study, primary tumors with known patient outcomes were assessed under clinical testing conditions (n = 420). The 40-GEP results were integrated with clinicopathologic risk factors. Kaplan-Meier and Cox regression analyses were performed for metastasis. Results: The 40-GEP test demonstrated significant prognostic value. Risk classification was improved via integration of 40-GEP results with clinicopathologic risk factor-based assessment, with metastasis rates near the general cutaneous squamous cell carcinoma population for class 1 and ≥50% for class 2B. Conclusion: Combining molecular profiling with clinicopathologic risk factor assessment enhances stratification of cutaneous squamous cell carcinoma patients and may inform decision-making for risk-appropriate management strategies.

KW - clinicopathologic risk factors

KW - cutaneous squamous cell carcinoma

KW - gene expression profile

KW - informed decision-making

KW - metastasis/metastatic risk

UR - http://www.scopus.com/inward/record.url?scp=85121608864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121608864&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-1277

DO - 10.2217/fon-2021-1277

M3 - Article

C2 - 34821148

AN - SCOPUS:85121608864

SN - 1479-6694

VL - 18

SP - 833

EP - 847

JO - Future Oncology

JF - Future Oncology

IS - 7

ER -

Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this